World High Life PLC - Investment Strategy Update London Stock Exchange
RNS Number : 0098Y
World High Life PLC
04 September 2020

4 September 2020



World High Life PLC

 ("World High Life" or the "Company")


Love Hemp momentum provides World High Life team with the opportunity to focus investment attention on innovative applications for medicinal cannabis, including synthetics, CBD, and Hemp

World High Life Plc (AQSE: LIFE) (OTCQB: WRHLF) is pleased to announce that, in accordance with the Company's investment strategy, and building upon momentum from its wholly owned subsidiary, London based Love Hemp Limited ("Love Hemp"), the Company is now actively considering investment targets in the medicinal cannabis space, including new technologies and synthetic cannabinoids with potential for wide applications in multiple jurisdictions.

"There are compelling opportunities to achieve our mandate, improving quality of life and wellness through innovations in medicinal cannabis, synthetic pharmaceutical derivatives, CBD and Hemp, with a number of investment opportunities that our team is actively pursuing," noted Mr. David Stadnyk, World High Life CEO.

World High Life Investment Strategy Highlights

·    Building on Love Hemp's continued growth, World High Life leadership is seeking new strategic investments in the medicinal cannabis sector, including pharmaceutical applications

·    Potential areas of interest include new technologies, synthetic cannabinoids, CBD, and Hemp, where they can be applied to scale globally

·    Within this scope, the Company intends to invest in and scale innovative, early stage, uses of cannabinoids, which have existing approvals in place to benefit patients/users

"The Love Hemp team is doing terrific work, advancing its business model under difficult circumstances, due to COVID-19, and growing on many fronts. That momentum has allowed our World High Life team to become more active on the investment side of our business as we see tremendous opportunities, especially in the cannabinoid pharmaceutical space" added Mr. Stadnyk.


For further information please contact:

David Stadnyk

Founder & CEO

North America: 1 (236) 521-7211  

North America toll-free: 1 (888) 616-WRHLF (9745)

+44 (0) 7926 397 675





AQSE Corporate Adviser

Mark Anwyl/Allie Feuerlein

Peterhouse Capital Limited

+44 (0) 20 7469 0930

Financial PR

Megan Ray/Madeleine Gordon-Foxwell


+44 (0) 20 7138 3222





For more information on World High Life please visit:


Market Abuse Regulation (MAR) Disclosure

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.


Cautionary Note Regarding Forward Looking Information

We seek safe harbour. Some statements contained in this news release are "forward looking information" within the meaning of securities laws. Forward looking information include, but are not limited to, statements regarding the use of proceeds of the non-brokered private placement and payment of the debt settlements. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", "believes" or variations of such words and phrases (including negative or grammatical variations) or statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved" or the negative connotation thereof. Investors are cautioned that forward-looking information is inherently uncertain and involves risks, assumptions and uncertainties that could cause actual results to differ materially. There can be no assurance that future developments affecting the Company will be those anticipated by management. The forward-looking information contained in this press release constitutes management's current estimates, as of the date of this press release, with respect to the matters covered thereby. We expect that these estimates will change as new information is received. We do not undertake to update any estimate at any particular time or in response to any particular event, except as required by law.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.